

Gastric cancer

Vincenzo Catalano^{a,*}, Roberto Labianca^b, Giordano D. Beretta^b,
Gemma Gatta^c, Filippo de Braud^d, Eric Van Cutsem^e

^a Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy

^b Ospedali Riuniti, Bergamo, Italy

^c Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

^d START Project and European Institute of Oncology, Milan, Italy

^e University Hospital Gasthuisberg, Leuven, Belgium

Contents

1. General information	210
1.1. Epidemiology	210
1.1.1. Incidence and mortality	210
1.1.2. Survival	211
1.1.3. Prevalence	211
1.2. Aetiology and risk factors	211
1.2.1. Aetiological factors	211
1.3. Early diagnosis	212
1.3.1. Screening	212
2. Pathology and biology	212
2.1. Biological data	212
2.1.1. Histogenesis	212
2.1.2. Dysplasia	212
2.2. Histological types	213
2.2.1. Histotypes	213
2.2.2. Early gastric cancer (EGC)	213
2.3. Grading	214
2.3.1. Clinical implications	214
2.4. Particular histological types considered elsewhere	214
2.4.1. Rare tumours	214
3. Diagnosis	214
3.1. Signs and symptoms	214
3.2. Diagnostic strategy	214
3.2.1. Diagnostic studies	214
3.2.2. Radiological techniques and their indication according to the diagnostic question	214
3.2.3. Endoscopy and pathologic assessment	215
3.2.4. Biological markers	215
4. Staging	215
4.1. Stage classifications	215
4.1.1. Criteria for stage classification	215
4.1.2. TNM Classification [77]	216
4.1.3. Stage grouping	216
4.2. Staging procedures	216
4.2.1. Preoperative staging: standard and optional procedures	216
4.3. Surgical staging	217

* Corresponding author. Tel.: +39 0721364094; fax: +39 0721364094.

E-mail address: catalano_v@yahoo.it (V. Catalano).

5.	Prognosis	217
5.1.	Prognosis of operable disease	217
5.1.1.	Prognostic and risk factors	217
5.1.2.	Biologic prognostic factors	218
6.	Treatment	219
6.1.	Overall treatment strategy	219
6.1.1.	Overall treatment strategy	219
6.2.	Surgical treatment	219
6.2.1.	Extent of gastric resection	219
6.2.2.	Role and extent of lymphadenectomy	219
6.2.3.	Role of splenectomy	220
6.2.4.	Role of distal pancreatectomy	220
6.3.	Neoadjuvant treatment	221
6.3.1.	Neoadjuvant chemotherapy	221
6.3.2.	Neoadjuvant radiotherapy	222
6.3.3.	Neoadjuvant immunotherapy	222
6.4.	Adjuvant treatment	222
6.4.1.	Adjuvant chemotherapy	222
6.4.2.	Meta-analysis of adjuvant chemotherapy trials	222
6.4.3.	Adjuvant intraperitoneal chemotherapy	223
6.4.4.	Adjuvant radiotherapy	223
6.4.5.	Adjuvant chemoimmunotherapy	223
6.4.6.	Adjuvant chemoradiotherapy	223
6.4.7.	Criteria for suggesting an adjuvant treatment	224
6.4.8.	Conclusions	224
6.5.	Treatment of localised and locally advanced disease	224
6.5.1.	Overall treatment strategy for stage 0, I, II, III, IV	224
6.6.	Treatment of metastatic disease	226
6.6.1.	Overall treatment strategy for stage IV M1	226
6.6.2.	FAM and FAM variants	226
6.6.3.	Fluorouracil, doxorubicin, and methotrexate	227
6.6.4.	Cisplatin-based chemotherapy	227
6.6.5.	Chemotherapy for metastatic disease: treatment versus supportive care	228
6.6.6.	Chemotherapy and quality of life	228
6.6.7.	Chemotherapy for metastatic disease: suggested schedules	229
6.6.8.	Surgical treatment of metastatic disease	230
6.6.9.	Other palliative treatments	230
7.	Late sequelae	230
8.	Follow-up	231
8.1.	General aims	231
8.2.	Suggested protocols	231
	References	231

Abstract

Gastric cancer is one of the most common cancers and one of the most frequent causes of cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have undergone important changes in the last decades, but the prognosis for gastric cancer patients remains poor, especially in more advanced stages. Surgery is the mainstay of treatment of this disease, even if it is associated with a high rate of locoregional and distant recurrence. There is ongoing debate regarding the role of adjuvant treatment. In advanced disease, palliation of symptoms, rather than cure, is the primary goal of patient management. Several combination therapies have been developed and have been examined in phase III trials; however, in most cases, they have failed to demonstrate a survival advantage over the reference arm. This review summarizes the most important recommendations for the management of patients with gastric cancer.

© 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: Gastric cancer; Surgery; Chemotherapy; Treatment; Review

1. General information

1.1. Epidemiology

1.1.1. Incidence and mortality

Stomach cancer is one of the most common cancers in Europe ranking fifth [1] after lung, prostate, colorectal and

bladder cancers in men and breast, colorectal, lung and cancer of the corpus uteri in women. In Europe, each year there are some 192,000 new cases, representing about 23% of all malignant neoplasms [2]. The male-to-female ratio in incidence rates is about 1.6:1 [2].

The incidence of stomach cancer is higher in lower social classes, but has for many years been declining steadily

Download English Version:

<https://daneshyari.com/en/article/9257626>

Download Persian Version:

<https://daneshyari.com/article/9257626>

[Daneshyari.com](https://daneshyari.com)